Pharmac decision to fund two treatment combinations and widen access to ibrutinib for CLL

We are very pleased to announce that Pharmac has announced new funded treatment options for people with chronic lymphocytic leukaemia (CLL).

From 1 May 2026, two fixed‑duration combination therapies, venetoclax + ibrutinib and venetoclax + obinutuzumab, will be funded as first‑line treatments.

Access to ibrutinib monotherapy is also being widened so it can be used as a second‑line option for anyone whose CLL has relapsed or caused intolerable side effects.

These changes will give more people access to modern, effective treatments and reduce pressure on hospital infusion services.

Pharmac has also updated criteria so people currently self‑funding can transition to funded treatment within six months.

❤️ We’re grateful to our members who have shared their stories, your voices, alongside the work of the CLLANZ Trust, have helped influence better options and outcomes.